Neda Huseinovic

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto et autres

Abstract PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable genomic aberrations. Patients …

kr, ch, es, br, it, ro, de, gb, us (code pays fourni par la source)

Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial

Susanne Tan, Stanislav Ignatenko, Frank Dietrich Wagner, Anuja Dokras et autres

Abstract Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and insulin resistance. The dual sodium‐glucose co‐transporter 1/2 inhibitor (SGLT1/2i) licogliflozin (LIK066) ameliorates hyperinsulinism in patients with diabetes and obesity. This study examines the effect of licogliflozin on androgens in women with PCOS. …

de, us, ch (code pays fourni par la source)

Functional Interactions between Drosophila bHLH/PAS, Sox, and POU Transcription Factors Regulate CNS Midline Expression of the slit Gene

Stephen T. Crews, Yanping Gao, Emily L. Niemitz, Yue Ma et autres

During

us (code pays fourni par la source)

Author response for "Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial"

Susanne Tan, Stanislav Ignatenko, Frank Dietrich Wagner, Anuja Dokras et autres

Licogliflozin versus Placebo in Women with Polycystic Ovary Syndrome (PCOS): A Randomised, Double-Blind, Phase 2 Trial

Susanne Tan, Stanislav Ignatenko, Frank Dietrich Wagner, Anuja Dokras et autres

de, us, ch (code pays fourni par la source)

Abstract 12892: Safety and Efficacy of LHW090 in Patients With Resistant Hypertension: Results of a Randomized, Double Blind, Parallel Group, Placebo-Controlled Study

B. Alexander Yi, Neda Huseinovic, Douglas Hom, Anisha E. Mendonza et autres

Background: Patients with resistant hypertension have a higher risk of cardiovascular morbidity and mortality. The current treatment options for patients with resistant hypertension are limited by ...

Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients

Susan E. Ide, Mona Motwani, Michael Rugaard Jensen, J. Wang et autres

3533 Background: AUY922 is a synthetic inhibitor of Heat Shock Protein 90. Disruption of the HSP90 chaperone hetero- complex results in the loss of repression of heat shock factor-1 (HSF1), and subsequent induction of HSP70. We evaluated HSP70 as a pharmacodynamic (PD) …

ch (code pays fourni par la source)